• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » FDA investigates stent “shrinkage” in Boston Scientific’s Ion, Promus stents, others

FDA investigates stent “shrinkage” in Boston Scientific’s Ion, Promus stents, others

November 21, 2011 By MassDevice staff

Ion stent

The FDA is investigating reports that the thinner design of next-generation drug-eluting stents, including Boston Scientific’s (NYSE:BSX) Ion and Promus models, might be prone to deforming after implantation.

At least two studies and one case study presented at a recent cardiology conference reported incidents in which either a Boston Scientific Ion or Promus stent deformed after it was deployed inside a coronary artery.

“FDA is actively working with manufacturers, including Boston Scientific, to better understand longitudinal stent deformation with respect to its causes, predisposing underlying anatomic conditions, operator techniques that can reduce the likelihood of its occurrence, and treatment strategies should it occur,” the agency told Reuters in a email.

Sign up to get our free newsletters delivered straight to your inbox

Although there’s been only one reported incident of deformation involving a Promus stent from among more than 4,600 implantations in clinical trials, according to the federal watchdog agency, “an unspecified number of significant adverse events had been reported to the agency,” according to the news service.

“At this time, additional data collection and analyses are ongoing, but the information available to date indicates that the Ion paclitaxel-eluting platinum chromium stent remains safe and effective when used for its approved indications,” the FDA said, according to Reuters.

An Irish study published earlier this month found that thinner stents may have lower longitudinal strength, potentially leading to stent thrombosis and a “catastrophic late complication” and leaving the target lesion unprotected, according to scientists at the Belfast Health & Social Care trust.

Dr. Cindy Grines, editor of the Journal of Interventional Cardiology, detailed a case in the journal’s October issue involving “marked shortening, deformation and accordion of the Ion coronary stent,” something she claimed she hasn’t seen before in 25 years of practicing cardiology.

The stent involved in the case shortened by about 35 percent, Grines wrote.

“We believe that accordion of the stent caused technical difficulties in rewiring the vessel and ultimately stent thrombosis, [and] thus is of serious concern. Although recent reports from Europe noted this phenomenon in the Element and Omega stents (similar family of stent designs), to my knowledge this is the first published case in the stent approved in the United States, the Ion stent,” she wrote. “Although this shortening phenomenon may just require an additional stent to ensure adequate coverage of the lesion, in our case it appeared that the stent may have deformed and involuted, further compromising the lumen and preventing additional device interventions.”

Citing data from a second bench test conducted by Abbott (NYSE:ABT) “showing that the Element family of stents (including the Omega and Ion) may shorten up to 46 percent under the force that an interventional cardiologist may exert to advance a post-dilation balloon or intravascular ultrasound device, Grines called the results “very disturbing.”

“Hopefully, there will soon be new recommendations regarding the use of stents of this particular design for our community of interventional cardiologists. Until further data are available, our institution will use the Ion stent cautiously, and only when alternatives are unavailable for the size under consideration,” wrote Grines, who is vice president of clinical and academic affairs at Detroit Medical Center’s Cardiovascular Institute and a professor at Wayne State University.

The Irish researchers looked at stents made by Boston Scientific and Abbott, as well as stents from Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ) and Biosensors International Group. Their study compared Abbott’s Xience V’s and Xience Prime’s 81-micrometer thickness, for example, with J&J’s 140-micrometer Cypher and Cypher Select Plus.

“Stents have a lot of different properties, which vary from one to another,” noted New York Presbyterian Hospital and Colombia University Medical Center director of cardiovascular research Dr. Gregg Stone during a conference call discussing the Belfast report. “Some stents will be more prone to this complication than others. The question is to understand how frequent it is, when does it occur, how to prevent it and how to manage it.”

But the problem may not be a design flaw, Stone told Reuters, citing instances in which the balloon used to implant the device or the guide wire that carries the stent catch or pull on the stent and deform it.

“It can happen with any stent if you’re aggressive enough with it,” he said. “The metal is very thin – it’s 3/1,000 of an inch thick, so depending on the material and configuration … some are more prone (to deformation) than others.

“It seems to be a rare phenomenon. Millions of these are implanted and there are just a handful of these cases,” he said.

“Someone needs to put the cases together and look at them and decide about the signal of adverse events,” Mayo Clinic cardiologist Dr. David Holmes told Reuters, noting that the exact cause of the problem is still unclear. “This absolutely warrants more study.

“If it’s a mechanical problem, it needs to be fixed mechanically. If it’s a procedure issue, we need to make sure the initial deployment is ideal and we can do that by using imaging studies,” Holmes said.

Filed Under: Drug-Eluting Stents, Food & Drug Administration (FDA), News Well, Wall Street Beat Tagged With: Abbott, Biosensors International Group Ltd., Boston Scientific, Cordis Corp., Johnson and Johnson, Stent Wars

In case you missed it

  • Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine
  • FDA accepts New Drug Application for Eyenovia pupil dilation tech
  • Axonics, Micro Systems Technologies partners to make rechargeable SNM device
  • SeaSpine ticks up on 6.2% sales growth in Q4, reports losses
  • Boston Scientific completes Preventice buy, divests BTG Pharmaceutical business
  • Philips appoints chief innovation and strategy officer
  • Silk Road Medical reports losses in Q4, sales up 13%
  • Inovio Pharmaceuticals posts Street-beating Q4, touts HPV trial results
  • Is there a link between Bell’s palsy and COVID-19 vaccines?
  • Tandem Diabetes Care appoints Dr. Jordan Pinsker as its medical director
  • FDA approves first robot-assisted system for transvaginal hysterectomy
  • 2 deaths reported in Medtronic HeartWare recall
  • Quidel wins FDA nod for at-home antigen test
  • Dentsply Sirona skyrockets on Street-beating Q4
  • Eurofins launches direct-to-consumer home COVID-19 PCR test
  • MedTech 100 Roundup: Small slide continues
  • Hologic acquires molecular diagnostic company for $159M

RSS From Medical Design & Outsourcing

  • Could this hydrogel repair a broken heart?
    European researchers have developed an injectable hydrogel that they say could help repair and prevent further damage to the heart muscle after a heart attack. The therapeutic effect of multiple injections of this hydrogel into the cardiac tissue was assessed during the first preclinical study of its kind, demonstrating its efficacy for cardiac tissue remodeling… […]
  • How EtO plants can avoid lawsuits, cope with stricter regulation
    If EtO industry actors take certain targeted steps now, they can minimize legal exposure, more efficiently manage litigation and be better situated for compliance once new federal regulations are established. Karen Cullinane, Goldberg Segalla The use of ethylene oxide (EtO) to sterilize medical devices came under renewed scrutiny after the Environmental Protection Agency concluded in… […]
  • FDA authorizes Q-Collar to help protect athletes’ brains
    The FDA announced today that it authorized the Q-Collar made by Q30 Sports Science for protecting the brain during sports activities. Q30 Sports Science’s Q-Collar is a C-shaped collar worn around the neck designed to apply compressive force to the neck and increase blood volume to help reduce movement of the brain within the cranial… […]
  • The top 7 medtech CEO quotes on COVID-19, one year later
    The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out. Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world… […]
  • Pfizer wins FDA nod to store COVID vaccine at normal freezer temps
    The FDA announced today that it is allowing undiluted, frozen vials of the Pfizer-BioNTech COVID-19 vaccine to be transported and stored for up to two weeks at conventional temperatures commonly found in pharmaceutical freezers. The decision should allow for wider distribution of the vaccine to sites that do not have ultra-low temperature freezers. Pfizer asked… […]
  • 8 drug delivery innovations you need to know
    The drug delivery space has seen plenty of innovation over the years, and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the… […]
  • Hoffer Plastics gains MedAccred certification again
    Injection molding company Hoffer Plastics (South Elgin, Ill.) announced that it has received the MedAccred re-certification from not-for-profit medtech audit provider MedAccred. MedAccred is a supply-chain oversight program of the Performance Review Institute. It conducts critical-process audits for its member OEMs to ensure their suppliers adhere to global regulations and requirements, and helps reduce the number… […]
  • UK passes post-Brexit medical device regulation
    The U.K. has enacted a new law governing medical devices and drugs, with a focus on patient safety. The Medicines and Medical Devices Act, introduced in July 2020, establishes the position of commissioner for patient safety to respond to public and patient complaints and concerns about drugs and medical devices. The law was necessitated by… […]
  • Integrated Polymer Solutions acquires IRP Group
    Integrated Polymer Solutions (“IPS”), a portfolio company of Arcline Investment Management, announced this week that it has acquired IRP Group. IRP designs and manufacturers elastomeric sealing components from its facilities in Southern California. Founded in 1999, the company is focused on the Class I and II medical device market as well as the aerospace &… […]
  • Interpower debuts plugs in new colors
    Interpower announced that its NEMA 5-20 hospital-grade plugs for use in North America now come in molded colors of clear, black or gray on 10-foot lengths of flexible cord. These molded plugs complement the company’s NEMA 5-20 hand-wired hospital-grade plugs. The North American 18A hospital-grade power cord on 14 AWG SJT cable and North American… […]
  • Portescap motors gain certification
    Portescap announced that its slotless brushless DC motors for respirators have received ISO 13485:2016 certification. Expanding on ISO 9001, this standard contains specific requirements for parts traceability and risk management activities throughout the design and development stages. It also requires process and software validations at defined intervals. Independent risk management and quality compliance firm DNV… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS